<DOC>
	<DOCNO>NCT02889874</DOCNO>
	<brief_summary>This randomise , phase III , non-inferiority trial evaluate radiation therapy versus observation follow breast conserve surgery plan endocrine therapy patient stage I breast cancer luminal A subtype define use Prosigna ( PAM50 ) Assay .</brief_summary>
	<brief_title>EXamining PErsonalised Radiation Therapy Low-risk Early Breast Cancer</brief_title>
	<detailed_description>Radiation therapy ( RT ) breast conserve surgery improve local control survival current standard care patient early breast cancer . However , breast cancer heterogeneous disease , absolute benefit RT individual patient varies substantially . Thus , press priority contemporary breast cancer management tailor RT utilisation individual recurrence risk identify patient unlikely benefit RT , thereby avoid morbidity cost over-treatment . It recognise select patient early breast cancer unlikely derive benefit RT breast conserving surgery . However , randomise trial consistently identify patient may safely omit RT use conventional clinical-pathologic characteristic . Breast cancer intrinsic subtypes distinguish gene expression profile show associated distinct clinical outcome . There substantial evidence support clinical validity multigene assay include PAM50-based Prosigna Assay identifies intrinsic subtypes generates Risk Recurrence score ( ROR ) quantify individual risk distant relapse . Multigene assay increasingly integrated clinical practice inform chemotherapy decision , highlight substantial practice change potential personalising use RT early breast cancer . A recent analysis archive tumour specimen 1,308 patient early breast cancer show significant association local recurrence risk PAM50-defined intrinsic subtypes ROR score . EXPERT present unique opportunity clinical public health importance optimise personalise local therapy early breast cancer precise , individualise quantification local recurrence risk identify low-risk patient RT breast conserve surgery may safely omit .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>registration study : 1 . Female patient age ≥ 50 year menopausal status . 2 . Primary tumour characteristic assess conventional histopathology : Unifocal histologically confirm invasive breast carcinoma Maximum microscopic size ≤2 cm Grade 1 2 histology ER PR positive ≥10 % tumour cell either biopsy breast conserve surgical specimen HER2 negative IHC ( score 0 1+ ) situ hybridisation ( ERBB2amplification Ratio ERBB2/centromeres &lt; 2.0 mean gene copy number &lt; 6 ) . Equivocal IHC score ( 2+ ) must assess ISH . 3 . Primary tumour must resect breast conserve surgery microscopically negative margin invasive carcinoma associate ductal carcinoma situ ( cancer cell adjacent inked edge/surface specimen ) reexcision show residual disease . 4 . Histologically confirm negative nodal status determine sentinel node biopsy axillary dissection . Patients pN0 ( i+ ) disease eligible study participation ( malignant cell ≤0.2 mm regional lymph node ( ) detect hematoxylineosin ( H &amp; E ) stain IHC , include isolated tumour cell ) . 5 . No evidence distant metastasis . 6 . Eligible willing adjuvant endocrine therapy . 7 . ECOG performance status 02 . 8 . Availability FFPE tumour block Prosigna ( PAM50 ) Assay . For randomization study , patient must fulfill follow criterion : 1 . Primary tumour characteristic assess Prosigna ( PAM50 ) Assay : Luminal A intrinsic subtype ROR score ≤60 Any one following regard criterion exclusion study : 1 . Primary tumour characteristic : Presence multifocal multicentric invasive carcinoma ductal carcinoma situ ; Evidence clinical pathologic T4 disease ( extension chest wall , oedema ulceration skin , satellite skin nodule , inflammatory carcinoma ) ; The invasive component primary tumour present microinvasion ; Grade 3 histology ; Presence lymphovascular invasion 2 . Contraindication unwillingness adjuvant endocrine therapy . 3 . Planned receive adjuvant chemotherapy biologic therapy breast cancer surgery , i.e . systemic therapy endocrine therapy permit . Any therapy unrelated cancer permit discretion investigator . 4 . Treated neoadjuvant endocrine therapy , chemotherapy biologic therapy prior breast cancer surgery . 5 . Prior breast thoracic RT condition . 6 . Preoperative breast image evidence disease aside primary carcinoma resect breast conserving surgery . 7 . Concurrent invasive breast carcinoma ductal carcinoma situ ( synchronous metachronous ) . 8 . Prior diagnosis invasive breast carcinoma ductal carcinoma situ either breast irrespective disease free interval . 9 . A diagnosis nonbreast malignancy &lt; 5 year prior randomisation follow exception : Patients diagnose carcinoma situ cervix , endometrium colon ; melanoma situ ; basal squamous cell carcinoma skin time prior randomisation exclude study participation . Patients diagnose nonbreast malignancy ≥5 year prior randomisation without evidence disease recurrence exclude study participation . 10 . Significant comorbidity preclude definitive RT breast cancer ( e.g . cardiovascular pulmonary disease , scleroderma , systemic lupus erythematosus ) . 11 . Life expectancy &lt; 10 year . 12 . Documented mutation BRCA1 , BRCA2 TP53 , high genetic risk breast cancer . 13 . Pregnant lactating patient . 14 . Inability register study ≤6 week last surgical procedure breast cancer . 15 . Inability commence RT ( randomise receive RT ) later 12 week last surgical procedure breast cancer . 16 . Inability provide write informed consent . 17 . Psychiatric , addictive , disorder precludes compliance protocol requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radiation therapy</keyword>
	<keyword>omission</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>breast cancer</keyword>
</DOC>